title: [Comparative clinical appraisal of the effectiveness and tolerability of paclitaxel-LANCE and taxol in combination chemotherapy for recurrences and platinum-refractory ovarian carcinoma].
abstract: A clinical appraisal of efficacy and tolerability of taxol (T) and a generic drug--paclitaxel--LANCE (P)--was carried out in two groups of patients with recurrences (9) or platinum-refractory ovarian carcinoma (17). In group I, patients aged 19-71 (mean age--47 yrs) had received 6-7 courses, while, in group II, patients aged 44-72 (mean age--52 yrs) who suffered tumor progression--15.0 courses of various chemotherapeutic regimens. Following standard premedication, T and P were injected 135 mg/sq., intravenously, dropwise, during 3 hrs, as a rule, either concurrently with platinum drugs or with hemzar. In the final analysis, there was no clinically significant difference in overall response--44-30% and 44-48%, respectively, nor any significant difference in side-effect incidence was reported.
authors.forename: M L
authors.initials: ML
authors.lastname: Gershanovich
authors.forename: E V
authors.initials: EV
authors.lastname: Makhnova
authors.forename: M E
authors.initials: ME
authors.lastname: Livshits
authors.forename: E I
authors.initials: EI
authors.lastname: Gulo
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use*; D017671:Platinum Compounds / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017671:Platinum Compounds; D017239:Paclitaxel